<DOC>
	<DOCNO>NCT00001023</DOCNO>
	<brief_summary>PER 03/10/94 AMENDMENT : PART B . To determine whether effect plasma drug level azithromycin rifabutin measure change plasma concentration-time curve ( AUC ) drug take concomitantly . ORIGINAL PRIMARY : To gain preliminary information safety tolerance clarithromycin azithromycin combination rifabutin ( three potential agent Mycobacterium avium-intracellulare ) HIV-infected patient CD4 count &lt; 200 cells/mm3 . ORIGINAL SECONDARY : To determine whether effect pharmacokinetics macrolide antibiotic rifabutin drug take concomitantly . To monitor effect rifabutin therapy dapsone serum level patient take dapsone PCP prophylaxis . To monitor effect macrolide/rifabutin combination therapy AZT ddI serum level . Two new macrolide antibiotic , clarithromycin azithromycin , rifabutin ( rifamycin derivative ) demonstrate vitro vivo activity Mycobacterium avium-intracellulare , common systemic bacterial infection complicate AIDS . Further information need , however , regard clinical pharmacokinetic interaction drug use combination .</brief_summary>
	<brief_title>The Safety Effectiveness Rifabutin , Combined With Clarithromycin Azithromycin , HIV-Infected Patients</brief_title>
	<detailed_description>Two new macrolide antibiotic , clarithromycin azithromycin , rifabutin ( rifamycin derivative ) demonstrate vitro vivo activity Mycobacterium avium-intracellulare , common systemic bacterial infection complicate AIDS . Further information need , however , regard clinical pharmacokinetic interaction drug use combination . AMENDED 03/10/94 ( Part B ) : Approximately 38 HIV-infected uninfected subject randomize receive azithromycin rifabutin ( Groups 3 4 ) daily 14 day , follow combination regimen drug 4 additional week . Patients follow weekly . Pharmacokinetic sampling perform day 14 , 15 , 42-45 . ORIGINAL : Sixty-eight patient randomly assign one four group ( 17 patient per group ) . They receive either clarithromycin azithromycin combination rifabutin one two different dose schedule . Patients receive medication 6 week undergo follow-up weekly drug administration week 8 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Primary secondary PCP prophylaxis TMP/SMX , dapsone , aerosolized pentamidine . Any approved therapy antiretroviral treatment , antiretroviral therapy available FDAsanctioned treatment IND treatment protocol . Patients must : AMENDED ( PART B ) : Either HIV infection OR HIV infection . CD4 count unspecified . ORIGINAL : Documented HIV infection . CD4 count &lt; 200 cells/mm3 within 90 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known Mycobacterium aviumintracellulare ( MAI ) bacteremia presence clinical syndrome compatible MAI ( i.e. , fever , weight loss , elevate LDH alkaline phosphatase ) . Fever = &gt; 38.5 deg C ( 100.4 deg F ) within 7 day prior study entry . Concurrent Medication : Excluded : Acute chronic use phenobarbital , carbamazepine , rifampin , dilantin , fluconazole , itraconazole , ketoconazole , ciprofloxacin , betablockers , clarithromycin . Oral contraceptive . Acute therapy AIDSrelated opportunistic infection malignancy , acute medical illness , infection . Maintenance therapy CMV , cryptococcal meningitis , toxoplasmosis . Cytotoxic chemotherapy . Patients follow prior condition exclude : History intolerance hypersensitivity study drug , macrolide antibiotic , rifampin . Three loose bowel movement per day within 3 month prior study entry . Unintentional weight loss &gt; = 5 percent body weight within 3 month prior study entry . Prior Medication : Excluded : Rifabutin within 30 day prior study entry . Clarithromycin azithromycin within 14 day prior study entry . Acute therapy AIDSrelated opportunistic infection malignancy , acute medical illness , infection within 28 day prior study entry . Prior Treatment : Excluded : Blood transfusion within 1 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Clarithromycin</keyword>
</DOC>